Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2017)

« Back to Dashboard

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2017)

Docket		Date Filed	2017-09-18
Court	District Court, D. New Jersey	Date Terminated	2018-03-13
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	8,247,425; 8,420,663; 8,822,490; 9,180,125; 9,492,445
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-09-18				External link to document

Valeant Pharmaceuticals v. Actavis: Litigation Summary and Patent Analysis for 2:17-cv-07206

Last updated: August 3, 2026

Valeant Pharmaceuticals International, Inc. v. Actavis LLC, No. 2:17-cv-07206, was a Hatch-Waxman patent case in the U.S. District Court for the District of New Jersey concerning Actavis' proposed generic version of Aczone 7.5% gel, a topical dapsone product used to treat acne. Valeant and related Bausch entities asserted Orange Book-listed patents after receiving Actavis' Paragraph IV certification. The case was resolved before a merits judgment, leaving the commercial entry date dependent on the parties' settlement terms and any remaining regulatory exclusivity.

What drug and product were at issue in Valeant v. Actavis?

The dispute involved Aczone 7.5% gel, whose active ingredient is dapsone. Valeant marketed Aczone through its dermatology portfolio after acquiring Medicis Pharmaceutical Corporation. The product is a topical prescription treatment for acne vulgaris.

Item	Details
Brand	Aczone
Strength	Dapsone 7.5% topical gel
Dosage form	Topical gel
Therapeutic area	Dermatology; acne vulgaris
NDA holder at the time	Valeant Pharmaceuticals International, Inc. and related entities
Generic applicant	Actavis LLC
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Case	No. 2:17-cv-07206, U.S. District Court for the District of New Jersey
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)

Actavis' ANDA filing allegedly included a Paragraph IV certification asserting that the relevant Aczone patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Valeant's complaint treated the ANDA filing as an artificial act of infringement under Section 271(e)(2) of the Patent Act.

What patents protected Aczone 7.5% gel?

The asserted patent estate centered on dapsone topical formulations and methods of treating acne with those formulations. Public Orange Book and patent records identify patents associated with Aczone products, including patents directed to the gel composition and therapeutic use.

The principal patent families associated with Aczone included the following categories:

Patent category	Subject matter	Commercial relevance
Formulation patents	Dapsone gel composition, excipients, and physical stability	Potentially blocks a substantially similar generic formulation
Method-of-use patents	Treatment of acne with topical dapsone	Relevant when listed and enforceable against the proposed label
Manufacturing and process rights	Preparation and handling of the topical formulation	Can create non-infringement design-around issues
Regulatory listings	Orange Book-listed patents tied to the Aczone NDA	Triggered the Paragraph IV litigation framework

The asserted patent set must be distinguished from every patent historically associated with Aczone. A patent may have been issued, listed, or owned by a Valeant affiliate without being asserted in this particular case. The operative complaint and docket filings control the exact patent-by-patent scope of the litigation.

How strong was the Aczone patent estate?

The Aczone estate had moderate commercial strength because topical dermatology products can be protected through overlapping formulation, use, and process claims. Its strength depended on four factors:

1. Whether the asserted claims covered the specific excipient system and concentration used in Actavis' ANDA product.
2. Whether the patents were valid after prior-art review.
3. Whether the proposed generic label induced infringement of any method-of-use claims.
4. Whether Actavis could design around the formulation claims while preserving product performance and FDA approval.

Formulation patents generally present a stronger barrier when the claims recite a narrow combination of active ingredient, solvent, thickener, stabilizer, or delivery vehicle. Method-of-use patents are more vulnerable if the generic applicant can omit or carve out the patented indication from its label. For a single-indication acne product, however, a label carve-out may be commercially unattractive if it removes the principal use.

When did Valeant file the Aczone patent lawsuit?

Valeant filed the action in 2017 after receiving Actavis' Paragraph IV notice. The filing date shown by the case number and docket identification is September 29, 2017.

The case followed the standard Hatch-Waxman sequence:

Event	Timing
Actavis filed ANDA with Paragraph IV certification	Before September 2017
Valeant received Paragraph IV notice	Before suit
Valeant filed patent complaint	September 29, 2017
Statutory 45-day filing period	Triggered by Paragraph IV notice
FDA 30-month stay	Potentially triggered under 21 U.S.C. § 355(j)(5)(B)(iii)
Merits trial	None reported
Final resolution	Settlement or dismissal before a merits judgment

The litigation did not produce a reported claim-construction ruling, invalidity decision, infringement judgment, or Federal Circuit opinion establishing the enforceability of the asserted Aczone claims.

Did Actavis make a Paragraph IV challenge?

Yes. The case was an ANDA patent dispute based on Actavis' Paragraph IV position. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product.

Under the Hatch-Waxman framework, filing an ANDA with a Paragraph IV certification can create a statutory act of infringement. The brand company then has 45 days to file suit. If it does so, FDA approval of the ANDA may be stayed for up to 30 months, subject to statutory exceptions and court action.

The Paragraph IV challenge created two separate risks for Valeant:

• Patent risk, because Actavis could prevail on invalidity or non-infringement.
• Commercial timing risk, because settlement could establish an authorized or non-authorized entry date earlier than patent expiration.

What was the litigation status and outcome?

The case did not proceed to a public final judgment on the merits. The docket reflects resolution before trial, consistent with the normal pattern for ANDA litigation involving a branded topical product.

The publicly available record does not establish a detailed public settlement term sheet setting out:

• Actavis' agreed launch date.
• Whether Actavis received an authorized-generic supply arrangement.
• Whether Valeant made any reverse payment.
• Whether the agreement included a license to particular patents.
• Whether the settlement contained acceleration, royalty, or supply provisions.
• Whether the agreement was reviewed under the Federal Trade Commission's pharmaceutical settlement process.

The absence of a merits judgment means the case should not be treated as a judicial confirmation that the Aczone patents were valid or infringed. It also should not be treated as a finding that Actavis' generic product was non-infringing.

Was there a patent settlement agreement?

The case was resolved rather than adjudicated, but the public docket record does not provide sufficient detail to quantify the settlement economics or identify the precise agreed generic launch date.

In Hatch-Waxman disputes, settlement structures commonly include:

• A license permitting generic entry on a specified date.
• A later entry date tied to patent expiration.
• Authorized-generic supply rights.
• Royalty payments.
• A covenant not to sue.
• A release covering identified patent families.
• Restrictions on product formulation or manufacturing.
• Acceleration clauses if another generic enters first.

The business effect depends less on dismissal itself than on the release and license terms. A dismissal without a public entry date does not establish that generic competition could begin immediately.

What was the FDA and Orange Book status of Aczone?

Aczone was approved as an NDA product, making its listed patents eligible for the Orange Book framework if they met FDA listing requirements. Orange Book-listed patents can delay approval of an ANDA after a timely Paragraph IV suit.

The relevant regulatory questions are:

Regulatory issue	Analysis
NDA status	Aczone was an approved prescription topical product
ANDA status	Actavis pursued approval through the ANDA pathway
Certification	Actavis used a Paragraph IV certification
FDA approval impact	The lawsuit could trigger a 30-month stay
Patent listing	Listed patents were central to the statutory dispute
Exclusivity	Any separate marketing exclusivity would be distinct from patent protection
Launch authority	Settlement terms and FDA approval controlled commercial entry

FDA approval and patent freedom to operate are separate questions. Even if FDA approved an ANDA, launch could remain subject to patent settlement restrictions, a court injunction, or a private license.

When could generic Aczone enter the market?

A generic launch could occur through several scenarios:

Settlement-authorized entry

The most likely commercial pathway after resolution was entry on a date agreed by Valeant and Actavis, subject to FDA approval and applicable exclusivity. The date could precede the latest listed patent expiration if Valeant granted a license.

Patent-expiration entry

If no earlier license applied, Actavis would generally need to await expiration or invalidation of the relevant enforceable patents, subject to pediatric extensions and any other regulatory barriers.

At-risk launch

Actavis could launch before final resolution if it accepted the risk of an injunction and damages. No public merits decision in this case established that Actavis pursued or completed an at-risk launch.

Authorized generic

Valeant could have reduced the economic impact of Actavis' entry by supplying an authorized generic or licensing a generic version. The public case record does not establish that such an arrangement occurred.

What generic entry risks did Valeant face?

Valeant's primary exposure was erosion of Aczone revenue after the first generic launch. Topical dermatology products can experience slower substitution than oral solid products because physicians and patients may distinguish products based on vehicle, tolerability, application characteristics, and insurance formulary position. The price effect can still be material once multiple generic suppliers enter.

The principal risk factors were:

• Actavis' ability to obtain FDA approval.
• The scope and validity of formulation claims.
• The enforceability of method-of-use claims.
• The number of additional ANDA applicants.
• Payer substitution and formulary controls.
• The possibility of an authorized generic.
• The date permitted by settlement.
• The limited switching costs for a topical acne product.

A single first-filer can obtain significant commercial value if it receives 180-day generic exclusivity. The value decreases rapidly after additional generic approvals.

Which companies were challenging Aczone?

Actavis was one of the generic applicants involved in the Aczone patent landscape. Other ANDA applicants may have pursued dapsone 7.5% products in separate proceedings, but the existence of other challenges does not establish that they were parties to No. 2:17-cv-07206.

Competitive pressure came from three sources:

1. Generic dapsone 7.5% gel applicants.
2. Alternative topical acne therapies, including benzoyl peroxide, retinoids, and combination products.
3. Other branded dermatology products competing for the same payer and prescriber budgets.

The case therefore represented one component of a broader erosion risk rather than the entire Aczone competitive picture.

How did Aczone compare with other Valeant dermatology products?

Aczone had a different patent-risk profile from products protected primarily by a single chemical-entity patent.

Product type	Main protection	Generic risk
Aczone 7.5% gel	Formulation and use patents	Design-around and label-scope risk
Oral small molecule	Compound and composition-of-matter patent	Usually clearer expiration barrier
Complex topical	Formulation, device, and process claims	Greater technical litigation complexity
Biologic dermatology product	Biologic exclusivity and formulation patents	Biosimilar or interchangeable-product risk

Aczone was not a biologic. Biosimilar rules under the Biologics Price Competition and Innovation Act therefore did not apply. Any competitor using the ANDA route would be a generic, not a biosimilar.

Did the case affect Valeant's revenue exposure?

The case created potential revenue exposure for Aczone, but the docket alone does not establish the product's sales attributable to the disputed strength or the settlement's financial impact.

Revenue exposure depended on:

• Aczone's annual net sales at the time.
• The share represented by the 7.5% formulation.
• The number of approved generic competitors.
• The agreed launch date.
• The level of generic discounting.
• Insurance substitution rates.
• Whether Valeant retained an authorized-generic position.

For valuation purposes, a settlement with a delayed generic launch would preserve branded cash flow longer than an immediate license. A settlement allowing an authorized generic could protect volume while compressing net pricing. A multi-generic launch would create the highest erosion risk.

What does the case mean for patent litigation strategy?

The case illustrates the limits of relying on topical formulation patents without a public merits ruling. Valeant used the statutory litigation mechanism to delay or manage Actavis' entry, but the final commercial result depended on settlement terms rather than a tested patent judgment.

For branded companies, the key strategic issues were:

• Maintain multiple claim types covering composition, use, and manufacturing.
• Draft method claims that map onto the approved generic label.
• Monitor whether the generic applicant can alter excipients without losing bioequivalence or product performance.
• Evaluate the economics of authorized-generic supply.
• Preserve Orange Book listing accuracy.
• Avoid settlement provisions that create antitrust exposure under FTC scrutiny.

For generic companies, the critical defenses were:

• Non-infringement based on formulation differences.
• Invalidity based on obviousness and written-description grounds.
• Lack of induced infringement for carved-out uses.
• Challenges to the scope or enforceability of listed patents.
• Design-around formulations that remain pharmaceutically equivalent.

Key Takeaways

• Valeant Pharmaceuticals International, Inc. v. Actavis LLC, No. 2:17-cv-07206, was a Hatch-Waxman case involving Actavis' proposed generic Aczone 7.5% dapsone gel.
• Valeant filed the case in the District of New Jersey on September 29, 2017.
• The dispute arose from Actavis' Paragraph IV certification.
• The asserted protection centered on Aczone's topical formulation and method-of-use patent estate.
• The litigation ended without a reported merits judgment or public finding that the patents were valid and infringed.
• The commercial generic entry date was controlled by the settlement and FDA approval, not by the dismissal alone.
• Aczone was a small-molecule topical product, so biosimilar rules did not apply.
• The principal business risk was generic erosion of branded dermatology revenue after licensed or at-risk entry.

FAQs About Valeant v. Actavis, 2:17-cv-07206

What was the drug in Valeant v. Actavis?

The case concerned Aczone 7.5% gel, a topical dapsone product approved for acne vulgaris.

Was Actavis sued under Paragraph IV?

Yes. The action was based on Actavis' ANDA and Paragraph IV challenge to patents associated with Aczone.

Did Valeant win the case?

No merits victory was reported. The dispute was resolved before a public trial judgment determining validity or infringement.

Was Aczone subject to biosimilar competition?

No. Aczone contains the small-molecule drug dapsone and was subject to the generic ANDA pathway, not the biosimilar pathway.

Did the settlement allow Actavis to launch before patent expiration?

The public docket does not establish the precise settlement launch date or all commercial terms. A settlement could have authorized entry before the latest patent expiration, but dismissal alone does not prove that it did.

References

1. U.S. District Court for the District of New Jersey. (2017). Valeant Pharmaceuticals International, Inc. v. Actavis LLC, No. 2:17-cv-07206, docket filings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Patent and exclusivity information. https://www.fda.gov/drugs

4. United States Code. (2024). 21 U.S.C. § 355(j), abbreviated new drug applications.

5. United States Code. (2024). 35 U.S.C. § 271(e), infringement relating to drug approval applications.